267 related articles for article (PubMed ID: 16686367)
1. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
2. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
[TBL] [Abstract][Full Text] [Related]
3. Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer.
Mohana S; Ganesan M; Agilan B; Karthikeyan R; Srithar G; Beaulah Mary R; Ananthakrishnan D; Velmurugan D; Rajendra Prasad N; Ambudkar SV
Mol Biosyst; 2016 Jul; 12(8):2458-70. PubMed ID: 27216424
[TBL] [Abstract][Full Text] [Related]
4. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
5. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
[TBL] [Abstract][Full Text] [Related]
6. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein.
Penzotti JE; Lamb ML; Evensen E; Grootenhuis PD
J Med Chem; 2002 Apr; 45(9):1737-40. PubMed ID: 11960484
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
8. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q
PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360
[TBL] [Abstract][Full Text] [Related]
9. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Bansal T; Jaggi M; Khar RK; Talegaonkar S
J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
[TBL] [Abstract][Full Text] [Related]
10. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach.
Estrada E; Molina E; Nodarse D; Uriarte E
Curr Pharm Des; 2010; 16(24):2676-709. PubMed ID: 20642431
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
Pajeva IK; Wiese M
J Med Chem; 2002 Dec; 45(26):5671-86. PubMed ID: 12477351
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
13. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.
Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
16. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies.
Prajapati R; Singh U; Patil A; Khomane KS; Bagul P; Bansal AK; Sangamwar AT
J Comput Aided Mol Des; 2013 Apr; 27(4):347-63. PubMed ID: 23612916
[TBL] [Abstract][Full Text] [Related]
17. Development of decision tree models for substrates, inhibitors, and inducers of p-glycoprotein.
Hammann F; Gutmann H; Jecklin U; Maunz A; Helma C; Drewe J
Curr Drug Metab; 2009 May; 10(4):339-46. PubMed ID: 19519342
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of p-glycoprotein--lead identification and optimisation.
Pleban K; Ecker GF
Mini Rev Med Chem; 2005 Feb; 5(2):153-63. PubMed ID: 15720285
[TBL] [Abstract][Full Text] [Related]
19. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
Erić S; Kalinić M; Ilić K; Zloh M
SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
[TBL] [Abstract][Full Text] [Related]
20. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
Desai PV; Sawada GA; Watson IA; Raub TJ
Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
